Mereo BioPharma Group (MREO) Osake Kurssi
Mereo BioPharma Group Kurssi
Mereo BioPharma Groupn nettomarginaali −294,7 % on laskenut verrattuna 34,9 %:iin muutama vuosi sitten.
Mereo BioPharma Group osakekurssi
Mereo BioPharma Group liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Mereo BioPharma Group -osakkeesta
Mereo BioPharma Group plc is primarily active in the pharmaceutical industry.
The business model of Mereo BioPharma Group plc is focused on the development and commercialization of innovative therapeutics for rare and specialty diseases. The company identifies unmet medical needs and aims to provide tailored treatment solutions for patients. Mereo BioPharma Group plc employs a strategic approach towards acquiring and advancing potential drug candidates through clinical trials, regulatory approval processes, and eventual commercialization. By leveraging its expertise in orphan and specialty drugs, Mereo BioPharma Group plc seeks to deliver value to patients, healthcare providers, and stakeholders while addressing significant medical challenges.
The main competitors of Mereo BioPharma Group plc in the market include established pharmaceutical companies such as Pfizer, Novartis, and GlaxoSmithKline. These global giants also focus on developing innovative therapies and treatments in the biopharmaceutical industry. Mereo BioPharma Group plc, however, distinguishes itself through its unique pipeline of novel drugs, targeting specific rare diseases and maximizing therapeutic potential. Despite competition, Mereo BioPharma Group plc's commitment to advancing its clinical programs and collaborations sets it apart in the market, ensuring patients have access to potential life-changing treatments.
Mereo BioPharma Group plc is a biopharmaceutical company specializing in the development of innovative therapeutics for rare diseases. Founded in 2015, Mereo BioPharma has a rich history of leveraging its expertise in orphan diseases and novel treatment approaches. The company is dedicated to addressing high unmet medical needs in areas such as osteogenesis imperfecta, alpha-1 antitrypsin deficiency, and oncology. As a global leader, Mereo BioPharma collaborates with renowned medical professionals, researchers, and partners to advance its pipeline of potential breakthrough therapies. With a passion for improving patients' lives, Mereo BioPharma remains committed to driving innovation in the field of rare diseases.
Mereo BioPharma Group plc has achieved several significant milestones. The company successfully completed a Phase 2b clinical trial for their product BPS-804, a potential treatment for osteogenesis imperfecta. Additionally, Mereo BioPharma Group plc received Fast Track designation from the U.S. Food and Drug Administration for their product BCT-197, a potential treatment for acute exacerbations of chronic obstructive pulmonary disease. The company also obtained Orphan Drug Designation from the European Medicines Agency for their product Setrusumab, intended for the treatment of osteogenesis imperfecta. These achievements demonstrate Mereo BioPharma Group plc's commitment to developing innovative treatments in the biopharmaceutical industry.
Mereo BioPharma Group plc is primarily present in multiple countries and regions. It has a strong presence in the United Kingdom, where its headquarters are located. Additionally, the company also operates in the United States, where it has established important partnerships and collaborations. Mereo BioPharma Group plc aims to expand its global footprint through its innovative biopharmaceutical solutions.
Mereo BioPharma Group plc is a leading biopharmaceutical company that upholds strong values and a dedicated corporate philosophy. With a focus on improving patient lives through novel therapies, Mereo BioPharma Group plc emphasizes innovation, integrity, and collaboration. The company strives to develop transformative medicines for rare and specialty diseases, while maintaining the highest standards of ethical conduct and transparency. Mereo BioPharma Group plc embraces a patient-centric approach and is committed to advancing healthcare by providing effective treatments and improved outcomes. Its dedication to scientific excellence and commitment to its stakeholders make Mereo BioPharma Group plc a trusted leader in the biopharmaceutical industry.
14 analyytikkoa arvioi tällä hetkellä Mereo BioPharma Group-osaketta: 10 suosittaa ostoa, 3 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat Mereo BioPharma Group-yhtiöltä 34,28 M USD liikevaihtoa ja −0,04 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Mereo BioPharma Group-osake noteerataan hintaan 0,31 EUR (0,35 USD).
Mereo BioPharma Group-osake (MREO) on listattuna 5 pörssissä, muun muassa: NASDAQ (MREO), London (0A9G.L), Frankfurt (MAH0.F), München (MAH0.MU), Hamburg (MAH0.HM).
Mereo BioPharma Group plc is an internationally active biopharmaceutical company that focuses on the development of innovative therapeutics for the treatment of serious diseases. The business model of Mereo is based on three pillars: Clinical Development, Manufacturing and Commercialization, and Strategic Partnerships. The Clinical Development division is the driving force of the company. Here, new therapeutics with high clinical relevance are developed and tested in clinical trials. The main focus is on diseases with high medical need such as bone diseases, pulmonary and cardiovascular diseases, and cancer. The products developed in the Clinical Development division include BPS-804, an innovative therapy for the treatment of the rare bone disease hypophosphatasia; MPH-966, a selective androgen receptor modulator for the treatment of androgen receptor-positive breast cancer; and Acumapimod, an anti-inflammatory drug for the treatment of patients with acute exacerbations of chronic obstructive pulmonary disease (COPD). The Manufacturing and Commercialization division deals with the production and distribution of the therapeutics. Here, Mereo works closely with strategic partners and contract manufacturers to meet high quality standards and regulatory requirements. An important partner is the leading CDMO Lonza, which supports Mereo in the production of BPS-804 and other products. The focus of the Strategic Partnerships division is on collaboration with other biopharmaceutical companies to expand development and marketing opportunities. For example, Mereo has formed a strategic partnership with Ultragenyx Pharmaceutical Inc. to jointly develop and market BPS-804 in the United States and Europe. Through such partnerships, Mereo can increase its innovation and reach. The business model of Mereo is based on a stringent and effective development process that takes into account all aspects of the product lifecycle, from research and development to production and marketing. The close collaboration with strategic partners and contract manufacturing companies allows Mereo to focus on its core competencies and ensure the provision of high-quality products. Overall, the business model of Mereo is an innovative, scalable, and forward-looking model that is built on a strong scientific foundation and focuses on the development of therapeutics with high clinical relevance. Through the consistent implementation of this model, Mereo has already made significant progress and is on a promising growth trajectory.
odotettu liikevaihto Mereo BioPharma Group on 34,28 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Mereo BioPharma Group on −27,05 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Mereo BioPharma Group:n hinta-voitto-suhde (P/E) on tällä hetkellä −9,57. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Mereo BioPharma Group-osakkeen arvostusta.
Mereo BioPharma Group:n hinta-myynti-suhde (P/S) on tällä hetkellä 7,55. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Mereo BioPharma Group-osakkeen arvostuskennuslukuna.
Mereo BioPharma Group:n Eulpool-laatuscore on 2/10.
Mereo BioPharma Group:n ISIN on US5894921072. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Mereo BioPharma Group:n WKN on A2PEYJ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Mereo BioPharma Group:n ticker on MREO. Tämä pörssinoteeraus käytetään Mereo BioPharma Group-osakkeiden kauppaan pörssissä.
Mereo BioPharma Group osake
Mereo BioPharma Group vertaisryhmä
Mereo BioPharma Group Ticker
Mereo BioPharma Group FIGI
Kaikki tunnusluvut ja syvällinen analyysi Mereo BioPharma Group:sta
Meidän osakeanalyysimme Mereo BioPharma Group-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Mereo BioPharma Group:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: